Clover Health CEO sells 4,839 Class A shares

Accepted by SEC EDGAR 07/17/2026 - 05:26 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Clover Health Investments, Corp. executive Jamie L. Reynoso, CEO, Medicare Advantage, sold 4,839 shares of Class A Common Stock on July 17, 2026, at a $4.53 weighted average price, in multiple trades between $4.35 and $4.63 per share, under a Rule 10b5-1 trading plan adopted March 12, 2026. Following this sale, Reynoso directly holds 2,814,640 shares of Class A Common Stock.

Insider Trade Summary 10b5-1

Net Seller: 4,839 shares

Net Sell 1 txn

Insider Reynoso Jamie L.

Role CEO, Medicare Advantage

Sold 4,839 shs ($22K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock F1, F2	4,839	$4.53	$22K

Holdings After Transaction: Class A Common Stock — 2,814,640 shares (Direct)

Footnotes (2)

1. F1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026.
2. F2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.35 to $4.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Key Figures

Shares sold: 4,839 shares Weighted average sale price: $4.53 per share Sale price range: $4.35–$4.63 per share +2 more

5 metrics

Shares sold 4,839 shares Class A Common Stock sold on July 17, 2026

Weighted average sale price $4.53 per share Reported price for the Class A Common Stock sale

Sale price range $4.35–$4.63 per share Price range of multiple transactions within the reported sale

Shares held after sale 2,814,640 shares Directly owned Class A Common Stock following the transaction

Rule 10b5-1 plan adoption date March 12, 2026 Adoption date of trading plan used for this sale

Key Terms

Rule 10b5-1 trading plan, weighted average price, Class A Common Stock

3 terms

Rule 10b5-1 trading plan regulatory

"was effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Class A Common Stock financial

"security_title": "Class A Common Stock""

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Clover Health (CLOV) insider Jamie L. Reynoso report selling?

Jamie L. Reynoso reported selling 4,839 shares of Clover Health Class A Common Stock. The sale occurred on July 17, 2026, and was executed under a Rule 10b5-1 trading plan previously adopted by the reporting person.

At what price did CLOV's CEO sell shares on July 17, 2026?

The reported sale used a $4.53 weighted average price per share. Footnotes state the shares were sold in multiple transactions at prices ranging from $4.35 to $4.63 per share, with full trade details available on request.

Was the CLOV insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the sale was effected pursuant to a Rule 10b5-1 trading plan. The plan was adopted by Jamie L. Reynoso on March 12, 2026, indicating the trades were pre-arranged rather than discretionary on the trade date.

How many CLOV shares does Jamie L. Reynoso hold after the sale?

After the reported transaction, Jamie L. Reynoso directly holds 2,814,640 shares of Clover Health Class A Common Stock. This post-transaction balance reflects ownership immediately following the 4,839-share sale on July 17, 2026.

Does this CLOV Form 4 report any options or derivative transactions?

No. The Form 4 reports a single sale of Class A Common Stock and shows no derivative transactions. The derivative summary is empty, and the transaction is classified as a non-derivative open-market or private sale of common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reynoso Jamie L.

(Last) (First) (Middle)

C/O CLOVER HEALTH INVESTMENTS, CORP.

NOT APPLICABLE

(Street)

WILMINGTON DELAWARE 19801

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CLOVER HEALTH INVESTMENTS, CORP. /DE [ CLOV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, Medicare Advantage

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	07/17/2026		S		4,839(1)	D	$4.53(2)	2,814,640	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.35 to $4.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Remarks:

	/s/Peter J. Rivas as attorney-in-fact for Jamie L. Reynoso	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)